Get the Stockscreener App
11.58
0.69%
-0.08
After Hours:
11.58
Ocular Therapeutix Inc stock is traded at $11.58, with a volume of 1.44M.
It is down -0.69% in the last 24 hours and up +24.78% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$11.66
Open:
$11.59
24h Volume:
1.44M
Relative Volume:
0.66
Market Cap:
$1.84B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-8.5778
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
-2.85%
1M Performance:
+24.78%
6M Performance:
+50.39%
1Y Performance:
+36.88%
1-Day Range:
$11.49
$11.81
1-Week Range:
$11.49
$12.35
52-Week Range:
$5.80
$12.35
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.58 | 1.86B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Does Ocular Therapeutix Inc. stock perform well during market downturnsLow Risk Guidance That Work - jammulinksnews.com
Using data filters to optimize entry into Ocular Therapeutix Inc.Risk Managed Intraday Trade Alerts Increase in Volume - metal.it
Quantitative breakdown of Ocular Therapeutix Inc. recent moveReliable Alerts for Daily Stock Movers Released - metal.it
Ocular Therapeutix Inc. Reaches Critical Trendline SupportTrend Analysis for Safer Trades Gains Popularity - metal.it
Can Ocular Therapeutix Inc. Rally Enough to Break EvenTechnical Entry Strategy for Beginners Explained - metal.it
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewswire
After Leaping 31% Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Are Not Flying Under The Radar - simplywall.st
Ocular Therapeutix Sets Q2 Earnings Date: Key Retina Biotech Updates Coming August 5 - Stock Titan
What is the risk reward ratio of investing in Ocular Therapeutix Inc. stockFinancial News Planner For Beginners - jammulinksnews.com
Ocular Hypertension Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitec - Barchart.com
Can Ocular's AXPAXLI Redefine Outcomes In Wet AMD? - RTTNews
Is Ocular Therapeutix Inc. stock overvalued or undervaluedRapidly growing investment returns - jammulinksnews.com
Is Ocular Therapeutix Inc. a growth stock or a value stockDynamic capital growth - jammulinksnews.com
Is it the right time to buy Ocular Therapeutix Inc. stockFree Investment Community - jammulinksnews.com
How strong is Ocular Therapeutix Inc. company’s balance sheetUnlock your portfolio’s hidden potential - jammulinksnews.com
What analysts say about Ocular Therapeutix Inc. stockExceptional market positioning - PrintWeekIndia
Is Ocular Therapeutix Inc. a good long term investmentPhenomenal trading returns - PrintWeekIndia
What drives Ocular Therapeutix Inc. stock priceExceptional profit velocity - Autocar Professional
Ocular Therapeutix Inc. Stock Analysis and ForecastFastest-growing stock picks - PrintWeekIndia
Ocular Therapeutix stock hits 52-week high at $11.78 - Investing.com
Ocular Therapeutix stock hits 52-week high at $11.78 By Investing.com - Investing.com Canada
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S Is Still On The Mark Following 42% Share Price Bounce - 富途牛牛
Ocular Therapeutix Announces Participation in Upcoming Scientific Conferences Focused on Retina Innovation - Quiver Quantitative
Ocular Therapeutix Participates in Upcoming Scientific Conferences - AInvest
Ocular Therapeutix Unveils Breakthrough Diabetic Retinopathy Treatment Data Across 3 Major Eye Conferences - Stock Titan
Published on: 2025-07-20 23:34:06 - PrintWeekIndia
(OCUL) Trading Report - news.stocktradersdaily.com
FMR LLC's Strategic Acquisition of Ocular Therapeutix Shares: A Financial Analysis - AInvest
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):